ArticleJournal of cardiovascular electrophysiology2025
Ventricular Tachycardia Ablation in Patients With Severely Decreased Left Ventricular Ejection Fraction.
Article in Journal of cardiovascular electrophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAblation of ventricular tachycardia (VT) is often performed in patients with structural heart disease. Procedural and delayed enhancement cardiac magnetic resonance imaging (DE-CMR) characteristics among patients with very severe cardiomyopathy (CM) and without left-ventricular assist devices (LVAD) have been incompletely described.
objectivesTo examine procedural and imaging characteristics of patients with very severely decreased ejection fractions undergoing VT ablation procedures.
methodsConsecutive patients with a left ventricular ejection fraction (EF) < 20% and without LVADs who underwent VT ablation were included. A composite outcome of survival free from VT, LVAD, or transplant was examined.
resultsTwenty-seven patients were included (64.1 ± 7.76 years; male n = 23, 88.5%; EF 12.8 ± 3%, LV end diastolic diameter 74 ± 11 mm, ischemic CM (n = 16, 60%), Nonischemic CM (n = 9, 52%), mixed CM (n = 2, 7%)). Twenty-five (93%) patients had failed amiodarone, 9 (33%) had a prior VT ablation, and 13 (48%) underwent ablation for VT storm. Scar was present in 22/23 patients with DE-CMR (intramural [n = 13], endocardial [n = 8], epicardial [n = 2], mixed components [n = 12]). DE-CMR scar corresponded to VT sites of origin in 18/22 patients (82%), excluding one patient with right ventricular VT, two with bundle-branch-reentry VT, and one-non-inducible patient. After 22 ± 19 months, VT occurred in 15/27(56%) patients, death 8/27(30%) and the composite outcome occurred in 22/27(82%) patients.
conclusionPatients with very severe cardiomyopathy undergoing VT ablation represent a high risk population, experiencing high rates of VT recurrence and death on midterm follow up. Despite severe remodeling, DE-CMR provides localizing information on the arrhythmia site of origin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.